177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A phase 1/2 trial of 177Lu-BetaBart in prostate cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, cervical cancer and endometrial cancer, run by Radiopharm Theranostics, Ltd, now recruiting.
Overview
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07189871 by Radiopharm Theranostics, Ltd, with 61 participants planned, started 2026-02-23 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-BetaBart.
Similar pages
not linked directly; found by shared links- TrialA Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
Shares Radiopharm Theranostics, Prostate cancer and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Radiopharm Theranostics and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares Prostate cancer and the tag pipeline.